tiprankstipranks
Alimera Sciences (ALIM)
NASDAQ:ALIM

Alimera Stock Analysis & Ratings

ALIM Stock Chart & Stats

Day’s Range$4.25 - $4.3
52-Week Range$3.94 - $10.50
Previous Close$4.27
Volume2.62K
Average Volume (3M)36.16K
Market Cap$29.76M
P/E Ratio-4.2
Beta1.49
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart ScoreN/A
EPS (TTM)-1.02


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ALIM FAQ

What was Alimera’s price range in the past 12 months?
Alimera lowest stock price was $3.94 and its highest was $10.50 in the past 12 months.
    What is Alimera’s market cap?
    Alimera’s market cap is $29.76M.
      What is Alimera’s price target?
      The average price target for Alimera is $9.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $11.00 ,the lowest forecast is $8.00. The average price target represents 123.53% Increase from the current price of $4.25.
        What do analysts say about Alimera?
        Alimera’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Alimera’s upcoming earnings report date?
          Alimera’s upcoming earnings report date is Aug 03, 2022 which is in 77 days.
            How were Alimera’s earnings last quarter?
            Alimera released its earnings results on May 09, 2022. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.743 by -$0.107.
              Is Alimera overvalued?
              According to Wall Street analysts Alimera’s price is currently Undervalued.
                Does Alimera pay dividends?
                Alimera does not currently pay dividends.
                What is Alimera’s EPS estimate?
                Alimera’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Alimera have?
                Alimera has 7,000,000 shares outstanding.
                  What happened to Alimera’s price movement after its last earnings report?
                  Alimera reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.743. Following the earnings report the stock price went down -7.339%.
                    Which hedge fund is a major shareholder of Alimera?
                    Among the largest hedge funds holding Alimera’s share is Deerfield Management Company, LP. It holds Alimera’s shares valued at N/A.

                      ---

                      Alimera Stock Analysis

                      Smart Score
                      N/A
                      Not Ranked
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $9.50
                      ▲(123.53% Upside)
                      Moderate Buy
                      This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Alimera Sciences

                      Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      EyePoint Pharmaceuticals
                      Regeneron
                      Clearside Biomedical
                      Adverum Biotechnologies
                      Rocket Pharmaceuticals

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis